Sofinnova Investments related stories
All articles and analysis
VC-backed Gyroscope postpones IPO plansLondon-based Gyroscope Therapeutics, a gene therapy company focused on treating eye diseases, has postponed its IPO plans, citing market conditions as the reason.
Gene therapy firm Gyroscope Therapeutics files to go publicGyroscope Therapeutics, a gene therapy company, has filed for an IPO.
Gyroscope Therapeutics lands $148m Series CGyroscope Therapeutics, a gene therapy company, has raised $148 million in Series C financing.
VC-backed Bolt Biotherapeutics debuts IPOBolt Biotherapeutics Inc has gone public after pricing its 11.5 million shares at $20 per share.
- Atsena Therapeutics rakes in $55m Series A
Atsena Therapeutics, a clinical-stage gene therapy company, has secured $55 million in Series A financing.
- Aerovate Therapeutics scoops up $72.6m Series A
Aerovate Therapeutics Inc, a biotech company, has raised $72.6 million in Series A funding.
- Bolt Biotherapeutics rakes in $93.5m Series C
Redwood City, California-based Bolt Biotherapeutics Inc, a biotechnology company, has raised $93.5 million in Series C financing.
Gilead Sciences to acquires stake in VC-backed PionyrGilead Sciences Inc has agreed to acquire 49.9 percent stake in Pionyr Immunotherapeutics Inc, a developer of cancer immunotherapies.
- Amplyx Pharmaceuticals procures $53m
San Diego-based Amplyx Pharmaceuticals, a developer of therapies for debilitating and life-threatening diseases in patients with compromised immune systems, has raised $53 million as part of a Series C extension, which brought the round to over $90 million.
- Sofinnova promotes one to GP and another to partner
Sofinnova Investments has promoted Dr. Maha Katabi to general partner and Dr. Sarah Bhagat to partner.